Evicenter
P&T meetings

Lirafugratinib

Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma

Also known as Lyrfigtu, RLY-4008
Regulatory submission
NDA submitted January 2026
158 sources

Section 6 of 6

References

158 sources

  1. Abou-Alfa et al. (2020) (opens in a new tab)
  2. Abou-Alfa et al. (2022) (opens in a new tab)
  3. Abou-Alfa et al. (2026) (opens in a new tab)
  4. American Cancer Society Key Statistics for Bile Duct Cancer (2024) (opens in a new tab)
  5. Anderson et al. (2023) (opens in a new tab)
  6. Arai et al. (2014) (opens in a new tab)
  7. Arnouts et al. (2026) (opens in a new tab)
  8. Banales et al. (2020) (opens in a new tab)
  9. Beal et al. (2021) (opens in a new tab)
  10. Benson et al. (2025) (opens in a new tab)
  11. Bilir et al. (2016) (opens in a new tab)
  12. Borad et al. (2023) (opens in a new tab)
  13. Brindley et al. (2021) (opens in a new tab)
  14. Buckarma et al. (2022) (opens in a new tab)
  15. Burris et al. (2024) (opens in a new tab)
  16. CADTH pemigatinib pharmacoeconomic review (2022) (opens in a new tab)
  17. CADTH pemigatinib reimbursement recommendation (2022) (opens in a new tab)
  18. CDA-AMC pemigatinib reimbursement recommendation (2025) (opens in a new tab)
  19. Chamberlain et al. (2021) (opens in a new tab)
  20. Chen et al. (2023) (opens in a new tab)
  21. Chen et al. (2024a) (opens in a new tab)
  22. Chen et al. (2024b) (opens in a new tab)
  23. Chueh et al. (2023) (opens in a new tab)
  24. ClinicalTrials.gov NCT04526106 (opens in a new tab)
  25. ClinicalTrials.gov NCT07359820 (opens in a new tab)
  26. Compass Therapeutics COMPANION-002 primary endpoint announcement (2025) (opens in a new tab)
  27. Cristinziano et al. (2021) (opens in a new tab)
  28. Ding et al. (2025) (opens in a new tab)
  29. DiPeri et al. (2024) (opens in a new tab)
  30. Duff et al. (2022) (opens in a new tab)
  31. Elevar Care Connect (2026) (opens in a new tab)
  32. Elevar Therapeutics and Relay Therapeutics licensing announcement (2024) (opens in a new tab)
  33. Elevar Therapeutics approval announcement (2026) (opens in a new tab)
  34. Elevar Therapeutics brand name announcement (2026) (opens in a new tab)
  35. Elevar Therapeutics EMA submission announcement (2026) (opens in a new tab)
  36. Elevar Therapeutics ESMO 2026 abstracts announcement (2026) (opens in a new tab)
  37. Elevar Therapeutics LYRFIGTU prescribing information (2026) (opens in a new tab)
  38. Elevar Therapeutics LYRFIGTU website (opens in a new tab)
  39. Elevar Therapeutics NDA submission announcement (2026) (opens in a new tab)
  40. Elevar Therapeutics priority review announcement (2026) (opens in a new tab)
  41. Elevar Therapeutics ReFocus202 first patient announcement (2026) (opens in a new tab)
  42. Ellis et al. (2026) (opens in a new tab)
  43. Facchinetti et al. (2024) (opens in a new tab)
  44. Facchinetti et al. (2026) (opens in a new tab)
  45. FDA Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics guidance (2018) (opens in a new tab)
  46. FDA Federal Register notice (2024) (opens in a new tab)
  47. FDA futibatinib multi-discipline review (2022) (opens in a new tab)
  48. FDA lirafugratinib approval notice (2026) (opens in a new tab)
  49. FDA LYTGOBI prescribing information (2025) (opens in a new tab)
  50. FDA NDA 220425 approval letter (2026) (opens in a new tab)
  51. FDA Ongoing Cancer Accelerated Approvals (2026) (opens in a new tab)
  52. FDA PEMAZYRE prescribing information (2022) (opens in a new tab)
  53. FDA TRUSELTIQ prescribing information (2021) (opens in a new tab)
  54. FDA Withdrawn Cancer Accelerated Approvals (2026) (opens in a new tab)
  55. Ferraz Gonçalves et al. (2021) (opens in a new tab)
  56. Genovesi et al. (2026) (opens in a new tab)
  57. Giuliani et al. (2026) (opens in a new tab)
  58. Goldstein et al. (2015) (opens in a new tab)
  59. González-Medina et al. (2024) (opens in a new tab)
  60. Goyal et al. (2017) (opens in a new tab)
  61. Goyal et al. (2019) (opens in a new tab)
  62. Goyal et al. (2023) (opens in a new tab)
  63. Goyal et al. (2025) (opens in a new tab)
  64. Graham et al. (2014) (opens in a new tab)
  65. Hollebecque et al. (2022) (opens in a new tab)
  66. Hollebecque et al. (2026a) (opens in a new tab)
  67. Hollebecque et al. (2026b) (opens in a new tab)
  68. ICER Reference Case (2025) (opens in a new tab)
  69. Incyte Form 10-K (2026) (opens in a new tab)
  70. Israel et al. (2021) (opens in a new tab)
  71. Jain et al. (2018) (opens in a new tab)
  72. Javle et al. (2021) (opens in a new tab)
  73. Javle et al. (2022) (opens in a new tab)
  74. Javle et al. (2026) (opens in a new tab)
  75. Kasi et al. (2024) (opens in a new tab)
  76. Kaupp-Roberts et al. (2016) (opens in a new tab)
  77. Kelley et al. (2023) (opens in a new tab)
  78. Kim et al. (2026a) (opens in a new tab)
  79. Kim et al. (2026b) (opens in a new tab)
  80. Lamarca et al. (2021) (opens in a new tab)
  81. Lamarca et al. (2026) (opens in a new tab)
  82. Li et al. (2025) (opens in a new tab)
  83. Liguori et al. (2026) (opens in a new tab)
  84. Liu et al. (2022) (opens in a new tab)
  85. Lowery et al. (2018) (opens in a new tab)
  86. Mahipal et al. (2025) (opens in a new tab)
  87. Mahipal et al. (2026) (opens in a new tab)
  88. McGregor et al. (2023) (opens in a new tab)
  89. Mosele et al. (2024) (opens in a new tab)
  90. Nakaoka et al. (2026) (opens in a new tab)
  91. Neumann et al. (2023) (opens in a new tab)
  92. NICE TA1005 committee discussion (2024) (opens in a new tab)
  93. NICE TA1005 information about futibatinib (2024) (opens in a new tab)
  94. NICE TA1005 recommendation (2024) (opens in a new tab)
  95. NICE TA1005 resource impact summary report (2024) (opens in a new tab)
  96. NICE TA1153 committee discussion (2026) (opens in a new tab)
  97. NICE TA1153 recommendation (2026) (opens in a new tab)
  98. NICE TA722 committee discussion (2021) (opens in a new tab)
  99. NICE TA722 information about pemigatinib (2021) (opens in a new tab)
  100. NICE TA722 recommendation (2021) (opens in a new tab)
  101. Oh et al. (2022) (opens in a new tab)
  102. Oh et al. (2025) (opens in a new tab)
  103. Parasuraman et al. (2023) (opens in a new tab)
  104. Pobel et al. (2026) (opens in a new tab)
  105. Relay Therapeutics dose escalation data announcement (2023) (opens in a new tab)
  106. Relay Therapeutics ESMO 2022 data announcement (2022) (opens in a new tab)
  107. Relay Therapeutics Form 10-K (2024) (opens in a new tab)
  108. Relay Therapeutics Form 10-K (2025) (opens in a new tab)
  109. Relay Therapeutics Form 10-K (2026) (opens in a new tab)
  110. Relay Therapeutics Form 10-Q (2026) (opens in a new tab)
  111. Relay Therapeutics Form 8-K (2023) (opens in a new tab)
  112. Relay Therapeutics tumor-agnostic data announcement (2023) (opens in a new tab)
  113. Rocha-Gomes et al. (2026) (opens in a new tab)
  114. Roskoski (2024) (opens in a new tab)
  115. Rousian et al. (2026) (opens in a new tab)
  116. Saverno et al. (2025) (opens in a new tab)
  117. Schönherr et al. (2024) (opens in a new tab)
  118. Schram et al. (2021) (opens in a new tab)
  119. Schram et al. (2023) (opens in a new tab)
  120. Schram et al. (2026) (opens in a new tab)
  121. Schultz et al. (2020) (opens in a new tab)
  122. SEER Cancer Stat Facts Liver and Intrahepatic Bile Duct Cancer (2026) (opens in a new tab)
  123. Shroff et al. (2022) (opens in a new tab)
  124. Siegel et al. (2026) (opens in a new tab)
  125. Silverman et al. (2021) (opens in a new tab)
  126. Silverman et al. (2022) (opens in a new tab)
  127. Spencer et al. (2023) (opens in a new tab)
  128. Spira et al. (2026) (opens in a new tab)
  129. Subbiah et al. (2023) (opens in a new tab)
  130. Sung et al. (2026) (opens in a new tab)
  131. Tai et al. (2017) (opens in a new tab)
  132. Tzanetakos et al. (2023) (opens in a new tab)
  133. Van Dyke et al. (2019) (opens in a new tab)
  134. Verma et al. (2025) (opens in a new tab)
  135. Verma et al. (2026) (opens in a new tab)
  136. Vogel and Ducreux (2025) (opens in a new tab)
  137. Vogel et al. (2023) (opens in a new tab)
  138. Vogel et al. (2024a) (opens in a new tab)
  139. Vogel et al. (2024b) (opens in a new tab)
  140. Wang et al. (2024a) (opens in a new tab)
  141. Wang et al. (2024b) (opens in a new tab)
  142. Wang et al. (2026) (opens in a new tab)
  143. Wei et al. (2026) (opens in a new tab)
  144. Winfree et al. (2024) (opens in a new tab)
  145. Wu et al. (2013) (opens in a new tab)
  146. Wu et al. (2024) (opens in a new tab)
  147. Wu et al. (2026) (opens in a new tab)
  148. Xie et al. (2025) (opens in a new tab)
  149. Xin et al. (2026) (opens in a new tab)
  150. Ye et al. (2023) (opens in a new tab)
  151. Yoo et al. (2021) (opens in a new tab)
  152. Yoo et al. (2025a) (opens in a new tab)
  153. Yoo et al. (2025b) (opens in a new tab)
  154. Yoon and Yoo (2026) (opens in a new tab)
  155. Yorio et al. (2024) (opens in a new tab)
  156. Zhang et al. (2025) (opens in a new tab)
  157. Zhang et al. (2026) (opens in a new tab)
  158. Zheng-Lin et al. (2026) (opens in a new tab)